Recognizing Lean Liver Disease in Clinical Practice Clinicians should consider metabolic liver disease in patients who present with: Normal BMI but central adiposity (increased waist circumference) Mildly elevated liver enzymes without a clear cause Dyslipidemia or insulin resistance features Fatty liver on incidental imaging Routine use of noninvasive tests such as FIB4, ELF score, or transient elastography can help stratify risk and guide hepatology referrals
Ray KK, Seshasai SRK, Wijesuriya S et al
Chinese bulk retatrutide vs Western alternatives The decision between Chinese and Western sourcing involves more than just price
These signals included dizziness (ROR, 1.30, 95% CI 1.271.33), tremor (1.37, 1.321.42), dysgeusia (1.72, 1.641.81), lethargy (1.24, 1.151.33), taste disorder (2.55, 2.332.80), presyncope (1.39, 1.251.54), parosmia (2.39, 2.072.75), allodynia (25.55, 21.7130.08), hypoglycemic unconsciousness (8.11, 6.949.46), brain fog (1.78, 1.512.10), hyperesthesia (1.40, 1.181.66), diabetic neuropathy (1.95, 1.612.36), hypoglycemic seizure (3.29, 2.324.66), ophthalmic migraine (3.14, 1.885.27), Wernickes encephalopathy (2.37, 1.394.04), diabetic hyperglycemic coma (3.07, 1.685.62), hyperglycemic unconsciousness (7.94, 4.2714.77), vagus nerve disorder (3.75, 1.927.32), and hyperglycemic seizure (5.85, 1.8118.90) (Fig
Immune System Findings from multiple studies have demonstrated that GLP-1 also regulates the immune system
The most recent developments regarding therapies based on incretin hormones (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) are likely to fundamentally change our therapy for type 2 diabetes mellitus (T2DM), obesity and conditions associated with diabetes and obesity, i
